spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  pegaptanib 

 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 13 Feb 2012
Valeant Pharmaceuticals to Acquire Eyetech
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 29 Jan 2010
Study Published in the American Journal of Ophthalmology Examines Investigational Use of Macugen in Patients With Branch Retinal Vein Occlusion (BRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 Oct 2006
EyeGate Pharma Starts U.S. Operations in Waltham, MA
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2006
OSI Pharmaceuticals Announces That Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jun 2006
OSI Pharmaceuticals and Pfizer Announce Phase IV Macugen(R)(pegaptanib sodium injection) Maintenance Trial in Neovascular Age-Related Macular Degeneration (AMD)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 5 Jun 2006
Results From a Randomized Phase II Trial Suggested the Combinations of Avastin(R) Plus Tarceva(R) and Avastin Plus Chemotherapy Improved Progression- Free Survival in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2006
Preliminary Topline Efficacy Results from Phase II Data Show Macugen(R) (pegaptanib sodium injection) Maintained or Improved Vision in over 90 Percent of Patients with Macular Edema Associated with Central Retinal Vein Occlusion (CRVO)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 May 2006
OSI Pharmaceuticals Summarizes Macugen(R) (pegaptanib sodium injection) Data Presented at Association for Research in Vision and Ophthalmology (ARVO) Meeting
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 May 2006
OSI Pharmaceuticals Announces Management Changes to Its Eye Disease Business Team
Biopharmaceuticals Personnel Ophthalmology
 HSMN NewsFeed - 17 Apr 2006
OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Feb 2006
OSI Pharmaceuticals Announces European Regulatory Approval for Macugen(R) (pegaptanib sodium injection)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 2 Feb 2006
European Commission Approves Macugen for Treatment of All Types of Wet Age-Related Macular Degeneration; First Treatment to Target Underlying Disease Process of Wet AMD
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 1 Feb 2006
OSI Pharmaceuticals Announces Fourth Quarter Net Sales for Tarceva(R)'s International Launch
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2006
PR Pharmaceuticals (PRP) Announces Collaboration With OSI Pharmaceuticals to Develop Sustained Release Formulation of Macugen(R) (pegaptanib sodium injection)
Biopharmaceuticals Ophthalmology
Return to NewsFeed  

 Additional items found! 26

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 26 additional stories matching:
pegaptanib
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.